Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

141. Vitamin D supplementation in patients with osteoporosis

Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Vitamin D supplementation in patients with osteoporosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Vitamin D supplementation in patients with osteoporosis. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions The purpose (...) of vitamin D supplementation is to improve bone and muscle health, thereby reducing the risk of osteoporosis-related fractures. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Bone Densitys; Dietary Supplements; Osteoporosis; Vitamin D; Vitamins Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200

2012 Health Technology Assessment (HTA) Database.

142. How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies

How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies Ferko NC, Borisova N, Airia P, Grima DT, Thompson MF Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to explore the effect of varying rebates, co-payments and delivery of drugs (oral or intravenous) on the cost-effectiveness of osteoporosis treatment, for managed care organisations. The authors concluded that the cost-effectiveness of the drugs varied considerably when these factors were

2012 NHS Economic Evaluation Database.

143. Fracture risk and zoledronic acid therapy in men with osteoporosis. Full Text available with Trip Pro

Fracture risk and zoledronic acid therapy in men with osteoporosis. Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis.In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion (...) <0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%).Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.).

2012 NEJM Controlled trial quality: predicted high

144. Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis

Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Cost effectiveness of secondary vs tertiary prevention for post-menopausal osteoporosis Mueller D, Gandjour A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness and budget impact of secondary plus tertiary prevention of osteoporosis by identifying post-menopausal women who were at increased risk of fractures, compared with tertiary prevention alone. The authors concluded that both prevention strategies were cost-effective compared with no prevention. Secondary plus tertiary prevention was more effective and more

2012 NHS Economic Evaluation Database.

145. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

146. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

147. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk.

Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Studies suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. ADA Websites Access news, member benefits and ADA policy Attend ADA's premier event Access cutting-edge continuing education courses Find evidence to support your clinical decisions Access member-only practice content Investing in better oral health for all. Together. Take advantage (...) suggest suboptimal compliance of bisphosphonate therapy for osteoporosis increases fracture risk. Arthur Jeske DMD, PhD; James Zahrowski DMD, MS, PharmD . Overview Systematic Review Conclusion Patient compliance of bisphosphonate therapy for osteoporosis appears to be suboptimal, which increases bone fracture risk. Critical Summary Assessment Dentists should monitor for bisphosphonate adverse effects and if discovered, communicate the medication risk versus benefit with the physician and counsel

2011 ADA Center for Evidence-Based Dentistry

148. Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. Full Text available with Trip Pro

Cost-effectiveness of different screening strategies for osteoporosis in postmenopausal women. The best strategies to screen postmenopausal women for osteoporosis are not clear.To identify the cost-effectiveness of various screening strategies.Individual-level state-transition cost-effectiveness model.Published literature.U.S. women aged 55 years or older.Lifetime.Payer.Screening strategies composed of alternative tests (central dual-energy x-ray absorptiometry [DXA], calcaneal quantitative (...) ultrasonography [QUS], and the Simple Calculated Osteoporosis Risk Estimation [SCORE] tool) initiation ages, treatment thresholds, and rescreening intervals. Oral bisphosphonate treatment was assumed, with a base-case adherence rate of 50% and a 5-year on/off treatment pattern.Incremental cost-effectiveness ratios (2010 U.S. dollars per quality-adjusted life-year [QALY] gained).At all evaluated ages, screening was superior to not screening. In general, quality-adjusted life-days gained with screening tended

2011 Annals of Internal Medicine

149. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines

Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines Canadian Agency for Drugs (...) and Technologies in Health Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Canadian Agency for Drugs and Technologies in Health. Bisphosphonates for the prevention of osteoporosis in patients treated with systematic corticosteroids: a review of the clinical evidence and guidelines. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH

2011 Health Technology Assessment (HTA) Database.

150. Zoledronic acid - Osteoporosis (postmenopausal women)

Zoledronic acid - Osteoporosis (postmenopausal women) Common Drug Review CDEC Meeting – October 19, 2011 Page 1 of 4 Notice of CDEC Final Recommendation – November 16, 2011 © 2011 CADTH CDEC FINAL RECOMMENDATION ZOLEDRONIC ACID – REQUEST FOR ADVICE (Aclasta – Novartis Pharmaceuticals Inc.) Indication: Osteoporosis (postmenopausal women) Recommendation: The Canadian Drug Expert Committee (CDEC) recommends that zoledronic acid be listed for women with postmenopausal osteoporosis who would (...) alendronate. 2. The cost of zoledronic acid is approximately five times that of generic alendronate. 3. The Committee recognized that there may be a small proportion of women who are otherwise eligible for jurisdictional funding of oral bisphosphonates but who are unable to take oral bisphosphonates and who may benefit from annual intravenous (IV) bisphosphonate therapy. Background: Zoledronic acid (marketed as Aclasta) has a Health Canada indication for: • Treatment of osteoporosis in postmenopausal

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

151. Whole-body vibration therapy for osteoporosis: state of the science. (Abstract)

Whole-body vibration therapy for osteoporosis: state of the science. Clinical guidelines for osteoporosis recommend dietary and pharmacologic interventions and weight-bearing exercise to prevent bone fractures. These interventions sometimes have low adherence and can cause adverse effects. A proposed alternative or adjunctive treatment is whole-body vibration therapy (WBV), in which energy produced by a forced oscillation is transferred to an individual from a mechanical vibration platform (...) . Whole-body vibration platforms are not approved by the U.S. Food and Drug Administration for medical purposes. This review provides a broad overview of important issues related to WBV therapy for prevention and treatment of osteoporosis. Relying on key informants and a search of the gray and published literature from January 2000 to August 2011, the investigators found that the designs of WBV platforms and protocols for their use vary widely. The optimal target population for the therapy

2011 Annals of Internal Medicine

152. The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis

The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: a network meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

153. The societal burden of poor persistence to treatment of osteoporosis in Sweden

The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden The societal burden of poor persistence to treatment of osteoporosis in Sweden Landfeldt E, Lundkvist J, Strom O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the societal burden of poor maintenance of prescribed treatments for osteoporosis and the cost-effectiveness of improving adherence. The authors concluded that poor persistence with the treatment of osteoporosis was an important and costly health burden, and it should be considered when evaluating interventions. Some key assumptions were made, but the methods were valid and the authors

2011 NHS Economic Evaluation Database.

154. Osteoporosis. (Abstract)

Osteoporosis. 21727287 2011 09 06 2013 06 25 1539-3704 155 1 2011 Jul 05 Annals of internal medicine Ann. Intern. Med. In the clinic. Osteoporosis. ITC1-1-15; quiz ITC1-16 10.7326/0003-4819-155-1-201107050-01001 Lewiecki E Michael EM eng Journal Article Review United States Ann Intern Med 0372351 0003-4819 0 Bone Density Conservation Agents 0 Calcium Compounds 1406-16-2 Vitamin D AIM IM Bone Density Conservation Agents therapeutic use Calcium Compounds therapeutic use Dietary Supplements (...) Exercise Female Humans Male Osteoporosis complications diagnosis prevention & control therapy Osteoporotic Fractures etiology Patient Education as Topic Risk Factors Vitamin D therapeutic use 2011 7 6 6 0 2011 7 6 6 0 2011 9 7 6 0 ppublish 21727287 155/1/ITC1-1 10.7326/0003-4819-155-1-201107050-01001

2011 Annals of Internal Medicine

155. Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Full Text available with Trip Pro

Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis Jonsson B, Strom O, Eisman JA, Papaioannou A, Siris ES, Tosteson A, Kanis JA Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods (...) , the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The aim was to estimate the cost-effectiveness of denosumab compared with various oral treatments for osteoporosis in postmenopausal women. The authors concluded that denosumab was a cost-effective alternative to oral osteoporosis treatments, particularly for patients at high risk of fracture, who were not expected to fully adhere to oral treatment. On the whole

2011 NHS Economic Evaluation Database.

156. Bazedoxifene (Conbriza)and osteoporosis

Bazedoxifene (Conbriza)and osteoporosis 2011. DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis - navarra.es Castellano | Euskara | Français | English Use the search tool! Search engine : : : : : : DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis DAR No 7. Bazedoxifene (Conbriza®) and osteoporosis Content tools Share it For every 5 radiological vertebral fractures avoided there is one case of thromboembolism Bazedoxifene is indicated in postmenopausal osteoporosis in women at increased

2011 Drug and Therapeutics Bulletin of Navarre (Spain)

157. Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. Full Text available with Trip Pro

Dietary calcium intake and risk of fracture and osteoporosis: prospective longitudinal cohort study. To investigate associations between long term dietary intake of calcium and risk of fracture of any type, hip fractures, and osteoporosis.A longitudinal and prospective cohort study, based on the Swedish Mammography Cohort, including a subcohort, the Swedish Mammography Cohort Clinical.A population based cohort in Sweden established in 1987.61,433 women (born between 1914 and 1948) were followed (...) up for 19 years. 5022 of these women participated in the subcohort.Primary outcome measures were incident fractures of any type and hip fractures, which were identified from registry data. Secondary outcome was osteoporosis diagnosed by dual energy x ray absorptiometry in the subcohort. Diet was assessed by repeated food frequency questionnaires.During follow-up, 14,738 women (24%) experienced a first fracture of any type and among them 3871 (6%) a first hip fracture. Of the 5022 women

2011 BMJ

158. Denosumab - Postmenopausal osteoporosis

Denosumab - Postmenopausal osteoporosis Common Drug Review CEDAC Meeting – January 19, 2011; CEDAC Reconsideration – March 22, 2011 Notice of CEDAC Final Recommendation – March 30, 2011 Page 1 of 6 © 2011 CADTH CEDAC FINAL RECOMMENDATION DENOSUMAB (Prolia – Amgen Canada Inc.) Indication: Postmenopausal Osteoporosis Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that denosumab be listed for women with postmenopausal osteoporosis who would otherwise be eligible (...) evaluation of denosumab compared with raloxifene, but had concerns regarding the comparability of the patient populations in the clinical trials that were used to inform the economic evaluation. Background: Denosumab is indicated by Health Canada for the treatment of postmenopausal women at high risk for osteoporotic (fragility) fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

159. Osteoporosis

Osteoporosis © 1998 Kaiser Foundation Health Plan of Washington. All rights reserved. 1 Osteoporosis Screening, Diagnosis, and Treatment Guideline Prevention 2 Screening Recommendations and Tests 2 Diagnosis 4 Treatment 5 Goals 5 Lifestyle Modifications/Non-Pharmacologic Options 5 Pharmacologic Options Osteoporosis 5 Low Bone Density (Osteopenia) 7 Patients on Long-term Corticosteroid Therapy 8 Follow-up/Monitoring 9 Patients With Low Bone Density Who Have Not Sustained a Fracture 9 Patients (...) by the individual patient. 2 Prevention The following are effective strategies for preventing osteoporosis: Consume adequate calcium and vitamin D. Grade A Engage in weight-bearing exercise. Grade B For more information, see the Adult Weight Management Guideline. Avoid tobacco use. Grade B For information on tobacco cessation, see the Tobacco Use Guideline. Screening Recommendations and Tests Table 1. Recommendations for when to order a DEXA Population eligible for screening Test(s) Frequency Women aged 65

2011 Kaiser Permanente Clinical Guidelines

160. The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands Full Text available with Trip Pro

The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands The cost effectiveness of zoledronic acid 5mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from (...) as a first-line treatment for the secondary prevention of fragility fractures in women with postmenopausal osteoporosis. The authors concluded that their analysis suggested that zoledronic acid was a cost-effective first-line option. The study methodology was adequate, but limited reporting on key evidence means that it is unclear if the authors' conclusions are appropriate. Type of economic evaluation Cost-utility analysis Study objective The study assessed the cost-effectiveness of zoledronic acid 5mg

2011 NHS Economic Evaluation Database.